XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.53
−1.67%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
Market Cap
$3.47M
MomentumView details →
1D Return
−1.67%
YTD Return
−75.48%
RSI (14)
31.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
Market Cap
$3.47M
RSI (14)
31.5
MomentumView details →
1D Return
−1.67%
YTD Return
−75.48%
SummaryUpdated Jun 1, 2026
Beyond Air, Inc. (NASDAQ:XAIR) is a commercial-stage medical device and biopharmaceutical company founded in 2018 and based in Garden City, New York. The company was formerly known as AIT Therapeutics, Inc. before changing its name in June 2019. Beyond Air specializes in developing nitric oxide-based therapeutic solutions, with its flagship product being the LungFit platform - a revolutionary nitric oxide generator and delivery system that creates therapeutic nitric oxide from ambient air rather than requiring traditional gas cylinders.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted Breakthrough Device Designation to Beyond Air's LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.4d agoBeyond Air entered a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries in exchange for equity and milestone payments.10d ago